首页 > 最新文献

Journal of Cancer Research and Clinical Oncology最新文献

英文 中文
Initial assessments by psycho-oncologists: predictors of distress and support needs. 心理肿瘤学家的初步评估:痛苦和支持需求的预测者。
IF 2.8 3区 医学 Q3 ONCOLOGY Pub Date : 2026-01-13 DOI: 10.1007/s00432-025-06419-z
Viktoria Ginger, Tanja Zimmermann

Purpose: Beyond standardized screenings, clinical assessments by psycho-oncologists during initial consultations play a key role in guiding psychosocial cancer care. Despite their relevance, these assessments have rarely been systematically examined. The aim of this study was to analyze psycho-oncologists' assessments of psychological distress and support needs and to identify factors influencing their assessments.

Methods: In a cross-sectional study, N = 9 psycho-oncologists retrospectively evaluated N = 1048 initial psychooncological consultations. The perceived psychological distress, depression, anxiety, health literacy and support needs of patients were recorded, as well as consultation-related conditions and the psycho-oncologists' own stress levels. Analyses involved descriptive statistics, group comparisons, correlations, and a binomial logistic regression.

Results: A distress score ≥ 5 was observed by psychooncologists in 74.7% of patients; 44.5% were rated as anxious, 28.6% as depressed. Mental health diagnoses were made in 25% of cases, mainly adjustment or affective disorders. Psycho-oncological support needs were identified in 75.6% of patients. Key predictors for identifying distress and needs included patients' desire for support (OR = 45.06), Knowledge and information about the consultation (OR = 2.66), and psycho-oncologists' own stress levels (OR = 1.53).

Conclusion: Psycho-oncological initial assessments are clinically relevant, but are subject to contextual and personal influences. The structured collection of consultation requests, information awareness, and health literacy, as well as interdisciplinary collaboration, can improve the assessment. The psychological stress of psycho-oncologists should also be systematically taken into account.

目的:除了标准化筛查之外,心理肿瘤学家在初次会诊期间的临床评估在指导心理癌症护理方面发挥着关键作用。尽管这些评价具有相关性,但很少得到系统的审查。本研究的目的是分析心理肿瘤学家对心理困扰和支持需求的评估,并确定影响其评估的因素。方法:在一项横断面研究中,N = 9名心理肿瘤学家回顾性评估N = 1048名初次心理肿瘤学咨询。记录患者感知到的心理困扰、抑郁、焦虑、健康素养和支持需求,以及与咨询相关的情况和心理肿瘤学家自己的压力水平。分析包括描述性统计、组比较、相关性和二项逻辑回归。结果:74.7%的患者被心理科医生诊断为抑郁评分≥5分;44.5%被评为焦虑,28.6%被评为抑郁。在25%的病例中进行了心理健康诊断,主要是适应性障碍或情感性障碍。75.6%的患者有心理肿瘤支持需求。识别痛苦和需求的关键预测因素包括患者对支持的渴望(OR = 45.06),咨询的知识和信息(OR = 2.66),以及心理肿瘤学家自己的压力水平(OR = 1.53)。结论:心理肿瘤初步评估与临床相关,但受环境和个人影响。有组织地收集咨询请求、信息意识和卫生素养以及跨学科合作可以改善评估。心理肿瘤学家的心理压力也应予以系统的考虑。
{"title":"Initial assessments by psycho-oncologists: predictors of distress and support needs.","authors":"Viktoria Ginger, Tanja Zimmermann","doi":"10.1007/s00432-025-06419-z","DOIUrl":"10.1007/s00432-025-06419-z","url":null,"abstract":"<p><strong>Purpose: </strong>Beyond standardized screenings, clinical assessments by psycho-oncologists during initial consultations play a key role in guiding psychosocial cancer care. Despite their relevance, these assessments have rarely been systematically examined. The aim of this study was to analyze psycho-oncologists' assessments of psychological distress and support needs and to identify factors influencing their assessments.</p><p><strong>Methods: </strong>In a cross-sectional study, N = 9 psycho-oncologists retrospectively evaluated N = 1048 initial psychooncological consultations. The perceived psychological distress, depression, anxiety, health literacy and support needs of patients were recorded, as well as consultation-related conditions and the psycho-oncologists' own stress levels. Analyses involved descriptive statistics, group comparisons, correlations, and a binomial logistic regression.</p><p><strong>Results: </strong>A distress score ≥ 5 was observed by psychooncologists in 74.7% of patients; 44.5% were rated as anxious, 28.6% as depressed. Mental health diagnoses were made in 25% of cases, mainly adjustment or affective disorders. Psycho-oncological support needs were identified in 75.6% of patients. Key predictors for identifying distress and needs included patients' desire for support (OR = 45.06), Knowledge and information about the consultation (OR = 2.66), and psycho-oncologists' own stress levels (OR = 1.53).</p><p><strong>Conclusion: </strong>Psycho-oncological initial assessments are clinically relevant, but are subject to contextual and personal influences. The structured collection of consultation requests, information awareness, and health literacy, as well as interdisciplinary collaboration, can improve the assessment. The psychological stress of psycho-oncologists should also be systematically taken into account.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"152 1","pages":"39"},"PeriodicalIF":2.8,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12799885/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145966102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic progress in leptomeningeal metastasis from EGFR mutant non-small cell lung cancer: a clinical medicine review. EGFR突变非小细胞肺癌轻脑膜转移的治疗进展:临床医学综述。
IF 2.8 3区 医学 Q3 ONCOLOGY Pub Date : 2026-01-09 DOI: 10.1007/s00432-025-06416-2
Tianyi Ding, Yuwen Xie, Ming Ding

Leptomeningeal metastasis in patients with Epidermal Growth Factor Receptor-mutant non-small cell lung cancer carries a dismal prognosis and is associated with profound neurological morbidity. Historically, therapeutic efficacy has been severely limited, leading to poor overall survival. This review aims to synthesize the recent, albeit incremental, advances in the multidisciplinary management of this devastating complication. We delve into the evolving landscape of treatment modalities, with a particular focus on the latest generation of tyrosine kinase inhibitors and their superior central nervous system penetration. The roles of conventional approaches, including radiotherapy (both whole-brain and focal) for symptom palliation and tumor control, and intrathecal chemotherapy, are critically re-evaluated in the modern context. Furthermore, we explore the rationale and early evidence for novel combination strategies. A significant portion of our analysis is dedicated to evaluating the pharmacodynamic mechanisms of action, optimizing dosing strategies, and interpreting clinical outcomes from key trials and real-world evidence. Central to the discussion are the persistent challenges of adequate blood-brain barrier penetration, the emergence of therapeutic resistance, and the management of overlapping toxicities. We also address the parallel progress in diagnostic neuro-imaging and cerebrospinal fluid liquid biopsies, which are enhancing early detection and disease monitoring. Finally, this review outlines future research directions, emphasizing the need for randomized controlled trials and a deeper understanding of the tumor microenvironment to foster a paradigm shift in the care of patients with leptomeningeal metastasis.

表皮生长因子受体突变的非小细胞肺癌患者的轻脑膜转移预后不佳,并与严重的神经系统疾病相关。从历史上看,治疗效果受到严重限制,导致总生存率较低。这篇综述的目的是综合最近,尽管增量,多学科管理的进展,这一毁灭性的并发症。我们深入研究不断发展的治疗方式,特别关注最新一代酪氨酸激酶抑制剂及其优越的中枢神经系统渗透。传统方法的作用,包括用于症状缓解和肿瘤控制的放射治疗(全脑和局灶放射治疗)以及鞘内化疗,在现代背景下被重新评估。此外,我们探讨了新的组合策略的基本原理和早期证据。我们的分析中有很大一部分致力于评估作用的药效学机制,优化给药策略,并从关键试验和实际证据中解释临床结果。讨论的核心是充分的血脑屏障穿透,治疗耐药性的出现以及重叠毒性的管理的持续挑战。我们还讨论了诊断性神经成像和脑脊液活检的平行进展,这些进展正在加强早期发现和疾病监测。最后,本文概述了未来的研究方向,强调需要随机对照试验和对肿瘤微环境的更深入了解,以促进脑膜轻脑膜转移患者护理的范式转变。
{"title":"Therapeutic progress in leptomeningeal metastasis from EGFR mutant non-small cell lung cancer: a clinical medicine review.","authors":"Tianyi Ding, Yuwen Xie, Ming Ding","doi":"10.1007/s00432-025-06416-2","DOIUrl":"10.1007/s00432-025-06416-2","url":null,"abstract":"<p><p>Leptomeningeal metastasis in patients with Epidermal Growth Factor Receptor-mutant non-small cell lung cancer carries a dismal prognosis and is associated with profound neurological morbidity. Historically, therapeutic efficacy has been severely limited, leading to poor overall survival. This review aims to synthesize the recent, albeit incremental, advances in the multidisciplinary management of this devastating complication. We delve into the evolving landscape of treatment modalities, with a particular focus on the latest generation of tyrosine kinase inhibitors and their superior central nervous system penetration. The roles of conventional approaches, including radiotherapy (both whole-brain and focal) for symptom palliation and tumor control, and intrathecal chemotherapy, are critically re-evaluated in the modern context. Furthermore, we explore the rationale and early evidence for novel combination strategies. A significant portion of our analysis is dedicated to evaluating the pharmacodynamic mechanisms of action, optimizing dosing strategies, and interpreting clinical outcomes from key trials and real-world evidence. Central to the discussion are the persistent challenges of adequate blood-brain barrier penetration, the emergence of therapeutic resistance, and the management of overlapping toxicities. We also address the parallel progress in diagnostic neuro-imaging and cerebrospinal fluid liquid biopsies, which are enhancing early detection and disease monitoring. Finally, this review outlines future research directions, emphasizing the need for randomized controlled trials and a deeper understanding of the tumor microenvironment to foster a paradigm shift in the care of patients with leptomeningeal metastasis.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"152 1","pages":"38"},"PeriodicalIF":2.8,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12789316/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145933638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between GRIm score and response to nivolumab monotherapy in patients with advanced malignant melanoma. 晚期恶性黑色素瘤患者的GRIm评分与纳武单抗单药治疗反应之间的关系
IF 2.8 3区 医学 Q3 ONCOLOGY Pub Date : 2026-01-08 DOI: 10.1007/s00432-025-06411-7
Sila Oksuz, Oguzcan Kinikoglu, Ugur Ozkerim, Deniz Isik, Heves Surmeli, Seval Ay, Utku Donem Gundogdu, Tugba Basoglu, Hatice Odabas, Nedim Turan

Background/objectives: Malignant melanoma is an aggressive skin cancer with significant metastatic potential. Immune checkpoint inhibitors (ICIs), particularly those targeting the PD-1 pathway, have revolutionized treatment, improving survival rates. A PD-1 inhibitor, Nivolumab, has demonstrated durable responses in advanced melanoma patients. However, response variability necessitates predictive biomarkers for patient stratification.

Methods: The Gustave Roussy Immune Score (GRIm Score) is a prognostic tool integrating lactate dehydrogenase (LDH), neutrophil-to-lymphocyte ratio (NLR), and albumin levels to predict ICI efficacy. This retrospective study evaluated the association between the GRIm Score and response to nivolumab monotherapy in 40 patients with stage IV malignant melanoma treated between 2020 and 2024. Patients were classified into low-risk (score 0-1) and high-risk (score 2-3) groups.

Results: Results showed that patients with a low GRIm Score had significantly longer median progression-free survival (21.4 vs. 6.3 months, p = 0.003) and overall survival (26.5 vs. 7.2 months, p < 0.001). Multivariate analysis confirmed the GRIm Score as an independent prognostic factor (HR: 1.593, 95% CI: 1.156-2.197, p = 0.004), surpassing the predictive power of its components.

Conclusions: This study is the first to validate the GRIm Score in malignant melanoma, suggesting it is a valuable biomarker for patient selection in immunotherapy trials. The findings highlight its potential in refining treatment decisions, though further validation in larger, multicenter cohorts is required.

背景/目的:恶性黑色素瘤是一种具有显著转移潜力的侵袭性皮肤癌。免疫检查点抑制剂(ICIs),特别是那些靶向PD-1途径的药物,已经彻底改变了治疗方法,提高了生存率。PD-1抑制剂Nivolumab在晚期黑色素瘤患者中显示出持久的疗效。然而,反应变异性需要预测患者分层的生物标志物。方法:Gustave Roussy免疫评分(GRIm评分)是一种预后工具,结合乳酸脱氢酶(LDH)、中性粒细胞与淋巴细胞比值(NLR)和白蛋白水平来预测ICI的疗效。这项回顾性研究评估了2020年至2024年间接受治疗的40例IV期恶性黑色素瘤患者的GRIm评分与对纳武单抗单药治疗的反应之间的关系。患者分为低危组(0-1分)和高危组(2-3分)。结果:结果显示,低GRIm评分患者的中位无进展生存期(21.4个月对6.3个月,p = 0.003)和总生存期(26.5个月对7.2个月,p)明显更长。结论:本研究首次验证了恶性黑色素瘤的GRIm评分,表明它是免疫治疗试验中患者选择的有价值的生物标志物。研究结果强调了其在改进治疗决策方面的潜力,尽管需要在更大的多中心队列中进一步验证。
{"title":"Association between GRIm score and response to nivolumab monotherapy in patients with advanced malignant melanoma.","authors":"Sila Oksuz, Oguzcan Kinikoglu, Ugur Ozkerim, Deniz Isik, Heves Surmeli, Seval Ay, Utku Donem Gundogdu, Tugba Basoglu, Hatice Odabas, Nedim Turan","doi":"10.1007/s00432-025-06411-7","DOIUrl":"10.1007/s00432-025-06411-7","url":null,"abstract":"<p><strong>Background/objectives: </strong>Malignant melanoma is an aggressive skin cancer with significant metastatic potential. Immune checkpoint inhibitors (ICIs), particularly those targeting the PD-1 pathway, have revolutionized treatment, improving survival rates. A PD-1 inhibitor, Nivolumab, has demonstrated durable responses in advanced melanoma patients. However, response variability necessitates predictive biomarkers for patient stratification.</p><p><strong>Methods: </strong>The Gustave Roussy Immune Score (GRIm Score) is a prognostic tool integrating lactate dehydrogenase (LDH), neutrophil-to-lymphocyte ratio (NLR), and albumin levels to predict ICI efficacy. This retrospective study evaluated the association between the GRIm Score and response to nivolumab monotherapy in 40 patients with stage IV malignant melanoma treated between 2020 and 2024. Patients were classified into low-risk (score 0-1) and high-risk (score 2-3) groups.</p><p><strong>Results: </strong>Results showed that patients with a low GRIm Score had significantly longer median progression-free survival (21.4 vs. 6.3 months, p = 0.003) and overall survival (26.5 vs. 7.2 months, p < 0.001). Multivariate analysis confirmed the GRIm Score as an independent prognostic factor (HR: 1.593, 95% CI: 1.156-2.197, p = 0.004), surpassing the predictive power of its components.</p><p><strong>Conclusions: </strong>This study is the first to validate the GRIm Score in malignant melanoma, suggesting it is a valuable biomarker for patient selection in immunotherapy trials. The findings highlight its potential in refining treatment decisions, though further validation in larger, multicenter cohorts is required.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"152 1","pages":"33"},"PeriodicalIF":2.8,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12783489/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145933481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Profiling and functional analysis of exosomal circRNAs from EBV-associated gastric carcinoma CSCs. ebv相关胃癌CSCs外泌体环状rna谱分析和功能分析。
IF 2.8 3区 医学 Q3 ONCOLOGY Pub Date : 2026-01-08 DOI: 10.1007/s00432-025-06414-4
Li-Ping Gong, Yi-Ting Shao, Yu Du, Li-Ping Sun, Lu-Ying Tang, Jian-Ning Chen
{"title":"Profiling and functional analysis of exosomal circRNAs from EBV-associated gastric carcinoma CSCs.","authors":"Li-Ping Gong, Yi-Ting Shao, Yu Du, Li-Ping Sun, Lu-Ying Tang, Jian-Ning Chen","doi":"10.1007/s00432-025-06414-4","DOIUrl":"10.1007/s00432-025-06414-4","url":null,"abstract":"","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"152 1","pages":"30"},"PeriodicalIF":2.8,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12783480/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145933619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Type I-interferon β induces a strong anti-tumour response in bladder cancer cells. i型干扰素β在膀胱癌细胞中诱导强烈的抗肿瘤反应。
IF 2.8 3区 医学 Q3 ONCOLOGY Pub Date : 2026-01-08 DOI: 10.1007/s00432-025-06409-1
Marlena Hesse, Max Iltzsche, Daniel Nahhas, Christian Thomas, Susanne Füssel, Barbara Kind

Purpose: For non-muscle invasive bladder cancer (NMIBC), instillation with Bacillus Calmette-Guérin (BCG) is a standard therapy. With a still unclear mechanism, instillation activates the innate immune system, resulting in an immunological effect on the tumour. The aim of this work was to investigate which bladder cancer (BLCA) cells can be activated by interferon (IFN) exposure.

Methods: The BLCA cell lines RT4 and SW780 were stimulated with IFN-α2, -β and -λ1 over 4-72 h. Quantitative PCR (qPCR) was used to determine the expression of IFN receptor subunits (RS) and selected interferon-stimulated genes (ISGs). Luciferase reporter assay was performed to detect the activation of the IFN responsive element (ISRE). Different signal transduction molecules of the JAK/STAT pathway were assessed by Western Blot to prove its activation in BLCA cells. The viability of the stimulated cells was measured by WST-1 assay and the apoptosis induction by caspase-3/7 assay.

Results: The JAK/STAT pathway was activated via the four RS. Upon long-term treatment, type I and type III IFNs significantly induced increased ISG expression and apoptosis induction of RT4 and SW780 cells, emphasising their antiproliferative and immunomodulatory activity. This activation was mediated by ISRE. IFN-β activated the JAK/STAT pathway with the greatest potency, highlighting its superior efficacy in modulating cellular responses in BLCA.

Conclusion: Activation of the innate immune system has the ability to trigger further infiltration of the tumour microenvironment (TME) with immune cells, which positively influence the TME in its type, density and immunofunctional orientation against BLCA.

目的:对于非肌性浸润性膀胱癌(NMIBC),卡介苗(BCG)是一种标准的治疗方法。其机制尚不清楚,滴注激活先天免疫系统,导致对肿瘤的免疫作用。这项工作的目的是调查哪些膀胱癌(BLCA)细胞可以被干扰素(IFN)激活。方法:用IFN-α2、-β和-λ1刺激BLCA细胞株RT4和SW780细胞4 ~ 72 h,采用定量PCR (qPCR)检测IFN受体亚单位(RS)和选定干扰素刺激基因(ISGs)的表达。荧光素酶报告试验检测IFN反应元件(ISRE)的激活。Western Blot检测JAK/STAT通路的不同信号转导分子,证实其在BLCA细胞中的活化作用。用WST-1法检测细胞活力,用caspase-3/7法检测细胞凋亡诱导情况。结果:JAK/STAT通路通过4种RS被激活,经长期治疗,I型和III型IFNs显著诱导RT4和SW780细胞ISG表达增加和凋亡诱导,增强其抗增殖和免疫调节活性。这种激活是由ISRE介导的。IFN-β最有效地激活了JAK/STAT通路,突出了其在调节BLCA细胞反应方面的优越功效。结论:先天免疫系统的激活能够触发免疫细胞进一步浸润肿瘤微环境(tumor microenvironment, TME),从而对肿瘤微环境的类型、密度和针对BLCA的免疫功能取向产生积极影响。
{"title":"Type I-interferon β induces a strong anti-tumour response in bladder cancer cells.","authors":"Marlena Hesse, Max Iltzsche, Daniel Nahhas, Christian Thomas, Susanne Füssel, Barbara Kind","doi":"10.1007/s00432-025-06409-1","DOIUrl":"10.1007/s00432-025-06409-1","url":null,"abstract":"<p><strong>Purpose: </strong>For non-muscle invasive bladder cancer (NMIBC), instillation with Bacillus Calmette-Guérin (BCG) is a standard therapy. With a still unclear mechanism, instillation activates the innate immune system, resulting in an immunological effect on the tumour. The aim of this work was to investigate which bladder cancer (BLCA) cells can be activated by interferon (IFN) exposure.</p><p><strong>Methods: </strong>The BLCA cell lines RT4 and SW780 were stimulated with IFN-α2, -β and -λ1 over 4-72 h. Quantitative PCR (qPCR) was used to determine the expression of IFN receptor subunits (RS) and selected interferon-stimulated genes (ISGs). Luciferase reporter assay was performed to detect the activation of the IFN responsive element (ISRE). Different signal transduction molecules of the JAK/STAT pathway were assessed by Western Blot to prove its activation in BLCA cells. The viability of the stimulated cells was measured by WST-1 assay and the apoptosis induction by caspase-3/7 assay.</p><p><strong>Results: </strong>The JAK/STAT pathway was activated via the four RS. Upon long-term treatment, type I and type III IFNs significantly induced increased ISG expression and apoptosis induction of RT4 and SW780 cells, emphasising their antiproliferative and immunomodulatory activity. This activation was mediated by ISRE. IFN-β activated the JAK/STAT pathway with the greatest potency, highlighting its superior efficacy in modulating cellular responses in BLCA.</p><p><strong>Conclusion: </strong>Activation of the innate immune system has the ability to trigger further infiltration of the tumour microenvironment (TME) with immune cells, which positively influence the TME in its type, density and immunofunctional orientation against BLCA.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"152 1","pages":"35"},"PeriodicalIF":2.8,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12783495/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145933399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AI-MDT: an automatic and intelligent multidisciplinary team consultations platform for lung cancer diagnosis. AI-MDT:肺癌诊断自动化、智能化多学科团队会诊平台。
IF 2.8 3区 医学 Q3 ONCOLOGY Pub Date : 2026-01-08 DOI: 10.1007/s00432-025-06413-5
Yunyou Liu, Fei Wang, Peng Wang, Zhen Zhou, Hongqian Wang, Jingyao Li, Yang Qiu, Haidong Wang, Siwei Miao

Purpose: Multidisciplinary team (MDT) consultations are crucial for managing pulmonary nodules, yet face challenges in efficiency, evidence-based decision support, and data utilization within the MDT process. We present an integrated artificial intelligence (AI)-MDT platform that serves as an assistive tool for lung cancer MDT workflows by incorporating AI across various processes.The aim of this study is to evaluate the clinical utility and preliminary efficacy of the AI-MDT platform.

Methods: The platform comprises three core modules: process automation, intelligent decision support, and diagnostic assistance. It integrates a real-time, evidence-based knowledge base powered by large language models and deep learning, with computer vision for automatic lesion detection and feature analysis. A web-based interface allows users to interact seamlessly with the AI-MDT platform.

Results: Since its implementation in November 2023 at a tertiary Grade A hospital in China, the platform has been involved in 879 consultations, including 811 patients. AI-generated diagnostic recommendations were utilized 852 times, and decision-making support was used in 744 cases. The platform significantly increased consultation volume, reduced expert time, and enhanced data utilization compared to traditional MDT.

Conclusions: It offers clinicians tools to improve diagnostic quality and work efficiency, highlighting its significant clinical application value. These findings suggest that the proposed platform contributes to the emerging research on advances precision lung cancer management by integrating a continually updated evidence base and intelligent imaging methodologies, having potential implications for MDT processes across various medical specialties.

目的:多学科团队(MDT)会诊对肺结节的管理至关重要,但在MDT过程中面临效率、循证决策支持和数据利用方面的挑战。我们提出了一个集成的人工智能(AI)-MDT平台,该平台通过跨各种流程整合AI,可作为肺癌MDT工作流程的辅助工具。本研究的目的是评估AI-MDT平台的临床应用和初步疗效。方法:该平台包括流程自动化、智能决策支持和诊断辅助三个核心模块。它集成了一个实时的、基于证据的知识库,由大型语言模型和深度学习提供支持,并与计算机视觉相结合,用于自动病变检测和特征分析。基于web的界面允许用户与AI-MDT平台进行无缝交互。结果:该平台自2023年11月在中国某三甲医院实施以来,共参与会诊879次,患者811例。人工智能生成的诊断建议使用了852次,决策支持使用了744例。与传统MDT相比,该平台显著增加了咨询量,减少了专家时间,并提高了数据利用率。结论:为临床医生提供提高诊断质量和工作效率的工具,具有重要的临床应用价值。这些发现表明,该平台通过整合不断更新的证据基础和智能成像方法,有助于推进精准肺癌管理的新兴研究,对不同医学专业的MDT过程具有潜在影响。
{"title":"AI-MDT: an automatic and intelligent multidisciplinary team consultations platform for lung cancer diagnosis.","authors":"Yunyou Liu, Fei Wang, Peng Wang, Zhen Zhou, Hongqian Wang, Jingyao Li, Yang Qiu, Haidong Wang, Siwei Miao","doi":"10.1007/s00432-025-06413-5","DOIUrl":"10.1007/s00432-025-06413-5","url":null,"abstract":"<p><strong>Purpose: </strong>Multidisciplinary team (MDT) consultations are crucial for managing pulmonary nodules, yet face challenges in efficiency, evidence-based decision support, and data utilization within the MDT process. We present an integrated artificial intelligence (AI)-MDT platform that serves as an assistive tool for lung cancer MDT workflows by incorporating AI across various processes.The aim of this study is to evaluate the clinical utility and preliminary efficacy of the AI-MDT platform.</p><p><strong>Methods: </strong>The platform comprises three core modules: process automation, intelligent decision support, and diagnostic assistance. It integrates a real-time, evidence-based knowledge base powered by large language models and deep learning, with computer vision for automatic lesion detection and feature analysis. A web-based interface allows users to interact seamlessly with the AI-MDT platform.</p><p><strong>Results: </strong>Since its implementation in November 2023 at a tertiary Grade A hospital in China, the platform has been involved in 879 consultations, including 811 patients. AI-generated diagnostic recommendations were utilized 852 times, and decision-making support was used in 744 cases. The platform significantly increased consultation volume, reduced expert time, and enhanced data utilization compared to traditional MDT.</p><p><strong>Conclusions: </strong>It offers clinicians tools to improve diagnostic quality and work efficiency, highlighting its significant clinical application value. These findings suggest that the proposed platform contributes to the emerging research on advances precision lung cancer management by integrating a continually updated evidence base and intelligent imaging methodologies, having potential implications for MDT processes across various medical specialties.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"152 1","pages":"32"},"PeriodicalIF":2.8,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12783485/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145933462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hypoalbuminemia as a prognostic marker for survival in biliary tract cancer: associations with tumor type, treatment and sex. 低白蛋白血症作为胆道癌患者生存的预后指标:与肿瘤类型、治疗和性别的关系
IF 2.8 3区 医学 Q3 ONCOLOGY Pub Date : 2026-01-08 DOI: 10.1007/s00432-025-06408-2
Mostafa Abdulrazzak, Linda Björkhem-Bergman, Christina Villard, Marco Gerling, Tina Gustavell, Hannes Jansson

Background: Albumin in combination with other inflammatory markers has shown prognostic value in malignancy, including biliary tract cancer (BTC). This study aimed to evaluate the prognostic value of hypoalbuminemia alone in patients with BTC, with stratified analyses according to tumor type, treatment and sex.

Methods: A retrospective regional referral center cohort study was conducted, including consecutive patients with a measurement of preoperative albumin and intended resection of suspected BTC: intrahepatic cholangiocarcinoma (iCCA), perihilar cholangiocarcinoma (pCCA) or gallbladder cancer (GBC) between 2009 and 2017. The primary outcome was overall survival (OS), analyzed by Kaplan-Meier estimate and Cox regression.

Results: Out of 221 patients, 191 underwent resection, while 30 patients were diagnosed with unresectable BTC (14%). In the resection group, 147 patients had confirmed BTC, while 44 (20%) were postoperatively diagnosed with a benign lesion. Hypoalbuminemia (< 35 g/L) was more frequent in pCCA (75%) and GBC (59%), compared to iCCA (34%, p < 0.001). The preoperative albumin level was positively associated with resectability (p = 0.025). In patients with resection, hypoalbuminemia was associated with a tumor positive resection margin (p < 0.001). Hypoalbuminemia was a negative prognostic factor in resectable (p < 0.001) and unresectable BTC (p < 0.001), and in both women (p = 0.002) and men (p = 0.004). Hypoalbuminemia was negatively associated with OS in iCCA (p < 0.001) and GBC (p = 0.022), but not in pCCA (p = 0.210).

Conclusion: Preoperative albumin was prognostic for survival in patients with iCCA and GBC, in both women and men and regardless of tumor resectability. Patients with pCCA more often had low albumin, and hypoalbuminemia alone was not prognostic in this subgroup.

背景:白蛋白联合其他炎症标志物在包括胆道癌(BTC)在内的恶性肿瘤中显示出预后价值。本研究旨在评估单独低白蛋白血症在BTC患者中的预后价值,并根据肿瘤类型、治疗和性别进行分层分析。方法:回顾性区域转诊中心队列研究,包括2009年至2017年间连续测量术前白蛋白并计划切除疑似BTC的患者:肝内胆管癌(iCCA)、肝门周围胆管癌(pCCA)或胆囊癌(GBC)。主要终点为总生存期(OS),采用Kaplan-Meier估计和Cox回归分析。结果:221例患者中,191例接受了切除,30例被诊断为不可切除的BTC(14%)。在切除组,147例患者确诊为BTC,而44例(20%)术后诊断为良性病变。结论:术前白蛋白是iCCA和GBC患者生存的预后因素,无论男女,无论肿瘤是否可切除。pCCA患者通常有低白蛋白,单独的低白蛋白血症对该亚组的预后没有影响。
{"title":"Hypoalbuminemia as a prognostic marker for survival in biliary tract cancer: associations with tumor type, treatment and sex.","authors":"Mostafa Abdulrazzak, Linda Björkhem-Bergman, Christina Villard, Marco Gerling, Tina Gustavell, Hannes Jansson","doi":"10.1007/s00432-025-06408-2","DOIUrl":"10.1007/s00432-025-06408-2","url":null,"abstract":"<p><strong>Background: </strong>Albumin in combination with other inflammatory markers has shown prognostic value in malignancy, including biliary tract cancer (BTC). This study aimed to evaluate the prognostic value of hypoalbuminemia alone in patients with BTC, with stratified analyses according to tumor type, treatment and sex.</p><p><strong>Methods: </strong>A retrospective regional referral center cohort study was conducted, including consecutive patients with a measurement of preoperative albumin and intended resection of suspected BTC: intrahepatic cholangiocarcinoma (iCCA), perihilar cholangiocarcinoma (pCCA) or gallbladder cancer (GBC) between 2009 and 2017. The primary outcome was overall survival (OS), analyzed by Kaplan-Meier estimate and Cox regression.</p><p><strong>Results: </strong>Out of 221 patients, 191 underwent resection, while 30 patients were diagnosed with unresectable BTC (14%). In the resection group, 147 patients had confirmed BTC, while 44 (20%) were postoperatively diagnosed with a benign lesion. Hypoalbuminemia (< 35 g/L) was more frequent in pCCA (75%) and GBC (59%), compared to iCCA (34%, p < 0.001). The preoperative albumin level was positively associated with resectability (p = 0.025). In patients with resection, hypoalbuminemia was associated with a tumor positive resection margin (p < 0.001). Hypoalbuminemia was a negative prognostic factor in resectable (p < 0.001) and unresectable BTC (p < 0.001), and in both women (p = 0.002) and men (p = 0.004). Hypoalbuminemia was negatively associated with OS in iCCA (p < 0.001) and GBC (p = 0.022), but not in pCCA (p = 0.210).</p><p><strong>Conclusion: </strong>Preoperative albumin was prognostic for survival in patients with iCCA and GBC, in both women and men and regardless of tumor resectability. Patients with pCCA more often had low albumin, and hypoalbuminemia alone was not prognostic in this subgroup.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"152 1","pages":"36"},"PeriodicalIF":2.8,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12783471/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145933616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acupuncture as treatment of cancer-therapy induced fatigue: a critical systematic review with a focus on the methodological assessment of blinding. 针灸治疗癌症引起的疲劳:一项关键的系统综述,重点是盲法的方法学评估。
IF 2.8 3区 医学 Q3 ONCOLOGY Pub Date : 2026-01-08 DOI: 10.1007/s00432-025-06395-4
Samuel Voigtländer, Jennifer Dörfler, Jutta Hübner

Background: Acupuncture is a method of traditional Chinese medicine that has been adapted in the Western world. The objective of this study was to critically assess the evidence presented in randomized controlled trials (RCTs) about the effectiveness of acupuncture on fatigue in cancer patients.

Method: In April 2024 a systematic search was conducted searching five electronic databases to find studies concerning the use, effectiveness and potential harm of acupuncture therapy on cancer patients.

Results: From all (1599) search results, 15 studies with 1346 patients were included. Acupuncture methods varied (e.g., traditional-, electro-, mind-regulating and ATAS-acupuncture) and were compared to sham acupuncture, usual care, or other controls. Studies comparing acupuncture to sham acupuncture reported mixed results: while some found significant effects on cancer-related fatigue, others found no advantages. Studies comparing acupuncture to usual care or waitlist controls often reported positive effects. However, the reliability of these findings is limited, as 14 of 15 studies were rated as "high risk of bias" by the RoB-2 tool due to issues like insufficient blinding and incomplete data analysis. Only one study, with low risk of bias, showed a significant reduction in fatigue with acupuncture compared to sham acupuncture (p < 0.001). GRADE evaluation also showed very low certainty of evidence.

Conclusion: The heterogenous results and methodological limitations of the existing studies prevent us from drawing definitive conclusions about the effectiveness of acupuncture in the treatment of cancer-related fatigue. Despite the inclusion of 15 studies, the overall evidence remains insufficient due to widespread problems in study design and inconsistent results. This analysis highlights the need to use more rigorous designs and more comprehensive assessment tools in future studies to better understand the role of acupuncture in the management of fatigue after cancer treatment.

背景:针灸是一种传统的中医方法,已被西方世界所采用。本研究的目的是批判性地评估随机对照试验(rct)中关于针灸治疗癌症患者疲劳的有效性的证据。方法:于2024年4月系统检索5个电子数据库,查找有关针灸治疗癌症患者的使用、疗效及潜在危害的研究。结果:在所有(1599)个检索结果中,纳入了15项研究,共1346例患者。针灸方法多种多样(例如,传统针灸、电针、精神调节和atas针灸),并与假针灸、常规护理或其他对照进行比较。比较针灸和假针灸的研究报告了不同的结果:一些研究发现针灸对癌症相关的疲劳有显著的效果,另一些研究发现没有任何好处。将针灸与常规护理或候补对照进行比较的研究通常报告了积极的效果。然而,这些发现的可靠性是有限的,因为15项研究中有14项由于盲法不足和数据分析不完整等问题被rob2工具评为“高偏倚风险”。只有一项低偏倚风险的研究显示,与假针灸相比,针灸能显著减轻疲劳(p结论:现有研究的结果异质性和方法学局限性使我们无法得出针灸治疗癌症相关疲劳有效性的明确结论。尽管纳入了15项研究,但由于研究设计普遍存在问题和结果不一致,总体证据仍然不足。这一分析强调了在未来的研究中需要使用更严格的设计和更全面的评估工具,以更好地了解针灸在癌症治疗后疲劳管理中的作用。
{"title":"Acupuncture as treatment of cancer-therapy induced fatigue: a critical systematic review with a focus on the methodological assessment of blinding.","authors":"Samuel Voigtländer, Jennifer Dörfler, Jutta Hübner","doi":"10.1007/s00432-025-06395-4","DOIUrl":"10.1007/s00432-025-06395-4","url":null,"abstract":"<p><strong>Background: </strong>Acupuncture is a method of traditional Chinese medicine that has been adapted in the Western world. The objective of this study was to critically assess the evidence presented in randomized controlled trials (RCTs) about the effectiveness of acupuncture on fatigue in cancer patients.</p><p><strong>Method: </strong>In April 2024 a systematic search was conducted searching five electronic databases to find studies concerning the use, effectiveness and potential harm of acupuncture therapy on cancer patients.</p><p><strong>Results: </strong>From all (1599) search results, 15 studies with 1346 patients were included. Acupuncture methods varied (e.g., traditional-, electro-, mind-regulating and ATAS-acupuncture) and were compared to sham acupuncture, usual care, or other controls. Studies comparing acupuncture to sham acupuncture reported mixed results: while some found significant effects on cancer-related fatigue, others found no advantages. Studies comparing acupuncture to usual care or waitlist controls often reported positive effects. However, the reliability of these findings is limited, as 14 of 15 studies were rated as \"high risk of bias\" by the RoB-2 tool due to issues like insufficient blinding and incomplete data analysis. Only one study, with low risk of bias, showed a significant reduction in fatigue with acupuncture compared to sham acupuncture (p < 0.001). GRADE evaluation also showed very low certainty of evidence.</p><p><strong>Conclusion: </strong>The heterogenous results and methodological limitations of the existing studies prevent us from drawing definitive conclusions about the effectiveness of acupuncture in the treatment of cancer-related fatigue. Despite the inclusion of 15 studies, the overall evidence remains insufficient due to widespread problems in study design and inconsistent results. This analysis highlights the need to use more rigorous designs and more comprehensive assessment tools in future studies to better understand the role of acupuncture in the management of fatigue after cancer treatment.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"152 1","pages":"37"},"PeriodicalIF":2.8,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12783427/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145933546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immature squamous metaplastic epithelium of Weber's glandular duct: a significant origin of HPV-independent oropharyngeal squamous cell carcinoma in the base of the tongue. 韦伯腺管的未成熟鳞状化生上皮:舌底不依赖hpv的口咽鳞状细胞癌的重要起源。
IF 2.8 3区 医学 Q3 ONCOLOGY Pub Date : 2026-01-08 DOI: 10.1007/s00432-025-06415-3
Xinyu Chen, Siyu Liu, Ping Li, Lin Luo, Lanzhu Lin, Qiaozhi Jiang, Dahai Yu, Renchuan Tao

Purpose: This study investigated the anatomical and pathological mechanisms of immature squamous metaplastic epithelium in Weber's glandular ducts at the tongue base in human papillomavirus (HPV)-independent oropharyngeal squamous cell carcinoma (OPSCC).

Methods: An analysis of 80 tongue base carcinoma cases clarified the anatomical connection to Weber's glands. Histological and immunohistochemical studies of these glandular ducts identified areas susceptible to cancer. A mouse model using 4-nitroquinoline-N-oxide was employed to simulate carcinogenic development.

Results: 42.5% of cases were linked to Weber's glands, with 20 directly connected to glandular ducts. Only one case was p16-positive, indicating that carcinogenesis in Weber's glandular ducts is largely non-HPV-mediated. The transformation zone with immature squamous metaplastic epithelium and CK17/p63+ reserve cells at Weber's glandular ducts were found, akin to cervical cancer susceptibility. CK17 studies indicated that the immature epithelium had "compromised barrier function" and "hyperproliferative activity", accelerating mutation and carcinogenesis. An atypical opening of the Weber's gland exposed the ductal epithelium to oncogenic factors, increasing carcinogenic risk. A mouse model confirmed the progression from metaplasia to carcinoma and the oncogenic potential of Weber's glandular ducts.

Conclusions: Weber's glandular ducts are an important origin of HPV-independent OPSCC. The first animal model replicating this process offers an essential platform for studying HPV-independent OPSCC.

目的:研究不依赖人乳头瘤病毒(HPV)的口咽鳞状细胞癌(OPSCC)舌基部韦伯腺管未成熟鳞状化生上皮的解剖和病理机制。方法:对80例舌底癌病例进行分析,明确其与韦伯腺的解剖关系。这些腺管的组织学和免疫组织化学研究确定了易患癌症的区域。采用4-硝基喹啉-n -氧化物小鼠模型模拟致癌性发展。结果:42.5%的病例与韦伯腺有关,20例直接与腺管相连。只有一例p16阳性,表明韦伯腺管的癌变主要是非hpv介导的。在韦伯腺管处发现未成熟的鳞状化生上皮和CK17/p63+储备细胞转化区,与宫颈癌易感性相似。CK17研究表明,未成熟上皮具有“屏障功能受损”和“超增殖活性”,加速突变和癌变。韦伯腺的非典型开口使导管上皮暴露于致癌因子,增加致癌风险。小鼠模型证实了从化生到癌的进展和韦伯腺管的致癌潜力。结论:韦伯腺管是hpv非依赖性OPSCC的重要来源。第一个复制这一过程的动物模型为研究hpv非依赖性OPSCC提供了一个重要的平台。
{"title":"Immature squamous metaplastic epithelium of Weber's glandular duct: a significant origin of HPV-independent oropharyngeal squamous cell carcinoma in the base of the tongue.","authors":"Xinyu Chen, Siyu Liu, Ping Li, Lin Luo, Lanzhu Lin, Qiaozhi Jiang, Dahai Yu, Renchuan Tao","doi":"10.1007/s00432-025-06415-3","DOIUrl":"10.1007/s00432-025-06415-3","url":null,"abstract":"<p><strong>Purpose: </strong>This study investigated the anatomical and pathological mechanisms of immature squamous metaplastic epithelium in Weber's glandular ducts at the tongue base in human papillomavirus (HPV)-independent oropharyngeal squamous cell carcinoma (OPSCC).</p><p><strong>Methods: </strong>An analysis of 80 tongue base carcinoma cases clarified the anatomical connection to Weber's glands. Histological and immunohistochemical studies of these glandular ducts identified areas susceptible to cancer. A mouse model using 4-nitroquinoline-N-oxide was employed to simulate carcinogenic development.</p><p><strong>Results: </strong>42.5% of cases were linked to Weber's glands, with 20 directly connected to glandular ducts. Only one case was p16-positive, indicating that carcinogenesis in Weber's glandular ducts is largely non-HPV-mediated. The transformation zone with immature squamous metaplastic epithelium and CK17/p63+ reserve cells at Weber's glandular ducts were found, akin to cervical cancer susceptibility. CK17 studies indicated that the immature epithelium had \"compromised barrier function\" and \"hyperproliferative activity\", accelerating mutation and carcinogenesis. An atypical opening of the Weber's gland exposed the ductal epithelium to oncogenic factors, increasing carcinogenic risk. A mouse model confirmed the progression from metaplasia to carcinoma and the oncogenic potential of Weber's glandular ducts.</p><p><strong>Conclusions: </strong>Weber's glandular ducts are an important origin of HPV-independent OPSCC. The first animal model replicating this process offers an essential platform for studying HPV-independent OPSCC.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"152 1","pages":"29"},"PeriodicalIF":2.8,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12783418/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145933582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Total neoadjuvant therapy for locally advanced rectal cancer: barriers to implementation in real-world practice. 局部晚期直肠癌的全新辅助治疗:在现实世界实践中实施的障碍。
IF 2.8 3区 医学 Q3 ONCOLOGY Pub Date : 2026-01-08 DOI: 10.1007/s00432-025-06412-6
David Rene Steike, Niklas Benedikt Pepper, Stefan Gravemeyer, Anne Bremer, Bernhard Glasbrenner, Matthias Brüwer, Andreas Pascher, Dirk Domagk, Lothar Biermann, Philipp Lenz, Hans Theodor Eich, Gabriele Reinartz
{"title":"Total neoadjuvant therapy for locally advanced rectal cancer: barriers to implementation in real-world practice.","authors":"David Rene Steike, Niklas Benedikt Pepper, Stefan Gravemeyer, Anne Bremer, Bernhard Glasbrenner, Matthias Brüwer, Andreas Pascher, Dirk Domagk, Lothar Biermann, Philipp Lenz, Hans Theodor Eich, Gabriele Reinartz","doi":"10.1007/s00432-025-06412-6","DOIUrl":"10.1007/s00432-025-06412-6","url":null,"abstract":"","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"152 1","pages":"31"},"PeriodicalIF":2.8,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12783395/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145933170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Cancer Research and Clinical Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1